Ascend Wellness Holdings, Inc.
Is there value inside this enterprise that the company is not currently capturing?
Filings through Jun 30, 2026 · Market data as of Sep 16, 2026
WE MODEL THE ENTERPRISE.™
01Executive summary
Ascend Wellness Holdings, Inc. enters the engine with $488.3M of trailing revenue, $66.0M of GAAP-derived EBITDA and a $374.0M enterprise value. Token Clear detected 4 value pathways from the company's own filings, led by IP & Brand Monetization, Structured Refinancing of High-Cost Debt and Treasury Optimization. Counted pathways model $9.3M–$24.3M of recurring annual economics, or $52.8M–$137.8M at today's multiple (14.1%–36.9% of current enterprise value) — against a 1% Thesis of $3.7M.
- Revenue grew -10.9% in the latest fiscal year.
02Current enterprise state
| Fact | Value | Class | Period | Source |
|---|---|---|---|---|
| Revenue (TTM) | $488.3M | CALCULATED | Jun 30, 2026 | 10-Q · filed 2026-08-12 |
| Revenue growth (latest FY) | -10.9% | CALCULATED | Dec 31, 2025 | FY 2025-12-31 revenue ÷ FY 2024-12-31 revenue − 1 |
| EBITDA (TTM, GAAP-derived) | $66.0M | CALCULATED | Jun 30, 2026 | Operating income + D&A |
| EBITDA margin (TTM) | 13.5% | CALCULATED | Jun 30, 2026 | EBITDA ÷ revenue |
| EBITDA margin FY2024 | 12.6% | CALCULATED | Dec 31, 2024 | (Operating income + D&A) ÷ revenue, prior fiscal year |
| Net income (TTM) | −$113.8M | CALCULATED | Jun 30, 2026 | 10-Q · filed 2026-08-12 |
| Operating cash flow (TTM) | $17.4M | CALCULATED | Jun 30, 2026 | 10-Q · filed 2026-08-12 |
| Capital expenditures (TTM) | $24.3M | CALCULATED | Jun 30, 2026 | 10-Q · filed 2026-08-12 |
| Free cash flow (TTM) | −$6.9M | CALCULATED | Jun 30, 2026 | Operating cash flow − capex |
| Cash & short-term investments | $67.0M | REPORTED | Jun 30, 2026 | 10-Q · filed 2026-08-12 |
| Total debt | $334.4M | REPORTED | Jun 30, 2026 | 10-Q · filed 2026-08-12 |
| Shareholders' equity | −$85.9M | REPORTED | Jun 30, 2026 | 10-Q · filed 2026-08-12 |
| Shares outstanding | 203.2M | REPORTED | Aug 10, 2026 | 10-Q · filed 2026-08-12 |
| Share price | $0.53 | REPORTED | Sep 16, 2026 | Yahoo Finance · OTC Markets OTCQX |
| Market capitalization | $106.7M | CALCULATED | Sep 16, 2026 | Share price × shares outstanding |
| Enterprise value | $374.0M | CALCULATED | Sep 16, 2026 | Market cap + total debt − cash & short-term investments |
| EV / EBITDA | 5.7× | CALCULATED | Sep 16, 2026 | Enterprise value ÷ EBITDA (TTM) |
03Evidence quality
04Value pathways
Ranked by deterministic Token Clear score. Each pathway lists the evidence that triggered it, the assumptions that size it, and what stands in its way.
Ascend Wellness Holdings, Inc. carries $196.0M of identified intangible assets plus $65.4M of goodwill (29.4% of total assets). Licensing and brand partnerships can earn incremental returns on assets already paid for.
Implied cost of debt is 20.7% on $334.4M of borrowings. Revenue-participation, convertible or asset-backed structures (including RPCST™-style instruments where permitted) are modeled to lower the all-in cost of capital.
Ascend Wellness Holdings, Inc. holds $67.0M of cash and short-term investments against an operating reserve of $48.8M (10% of TTM revenue). A tiered treasury policy on the $18.2M above reserve can raise yield without reducing liquidity coverage.
A board-approved policy could allocate 0.5%–2.0% of the $18.2M excess liquidity to digital-asset reserves tied to a defined strategic purpose. Returns are price-dependent and are not modeled.
05Financial scenarios
| Scenario | Pathway EBITDA | Modeled EBITDA | EV at today's 5.7× | vs. today |
|---|---|---|---|---|
| Today (reported) | $0.00 | $66.0M | $374.0M | 0.0% |
| Conservative | $9.3M | $75.3M | $426.9M | 14.1% |
| Base | $16.8M | $82.8M | $469.4M | 25.5% |
| Strategic | $24.3M | $90.3M | $511.9M | 36.9% |
Scenario columns apply the low, midpoint and high end of every counted pathway range. The peer column isolates a market re-rating and is shown for sensitivity only.
06Multiple Intelligence™
| Driver | Ascend Wellness Holdings, Inc. | Peer median | Read |
|---|---|---|---|
| Revenue growth | -10.9% | — | data required |
| EBITDA margin | 13.5% | — | data required |
| FCF conversion | -10.5% | — | data required |
| Return on invested capital | -4.6% | — | data required |
| Net leverage | 4.1× | — | data required |
| Capex intensity | 5.0% | — | data required |
| Stock comp / revenue | 0.5% | — | data required |
Peer set (0 valid of 0): none configured.
07The 1% Thesis™ — validated bottom-up
08Recommended sequence & 90-day proof of value
- • IP & Brand Monetization
- • Structured Refinancing of High-Cost Debt
- • Treasury Optimization
- • Reserve Diversification Policy (Digital Assets)
| Days 1–15 | Validate | Confirm reported facts, peer set and every ASSUMPTION with Ascend Wellness Holdings, Inc. finance leadership; close DATA REQUIRED gaps from primary filings. |
| Days 16–45 | Design | Detailed design for NOW pathways: IP & Brand Monetization, Structured Refinancing of High-Cost Debt, Treasury Optimization. Counsel review of regulatory blockers. |
| Days 46–75 | Approve & activate | Human approval gate per pathway; activate approved pathways with defined owners and baselines. |
| Days 76–90 | Measure | Baseline vs. target vs. actual on the first measurable metrics; decide on NEXT pathways and a platform engagement. |
09Risks & dependencies
- Securities-law, lender consent and rating-agency review.
- Accounting, custody and board risk-appetite approval required.
10Methodology & disclosures
Evidence classes. REPORTED taken from SEC XBRL filings or delayed market data · CALCULATED deterministic derivation with formula · BENCHMARK live peer comparable · ASSUMPTION explicit, challengeable input · SCENARIO output of stated assumptions.
Calculations. Trailing-twelve-month figures are fiscal year + current year-to-date − prior year-to-date. EBITDA is operating income plus depreciation and amortization (GAAP-derived, excluding non-GAAP adjustments). Enterprise value is market capitalization plus total debt less cash and short-term investments, excluding leases, minority interest and preferred equity. Non-USD filers are converted at spot. Recurring pathway economics are valued at today's multiple; overlapping pathways are counted once and contingent pathways are excluded.
Governance. AI does not perform or override valuation arithmetic. Scoring configuration is confidential and server-side. No pathway proceeds without human approval.
Disclosure. This study provides enterprise-value intelligence, scenario modeling and strategic analysis. Illustrative scenarios are not forecasts, guarantees, investment recommendations or assurances of market valuation. Market prices and valuation multiples are determined by investors and market conditions. Certain strategies require legal, tax, accounting, regulatory and other professional review before implementation.